Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bozitinib + Chemotherapy for MET-Altered NSCLC
NCT07153770Phase 2Not yet recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Sep 2025
- Primary completion
- Sep 2027
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of vebreltinib in non-small cell lung cancer (NSCLC), sponsored by Shanghai Pulmonary Hospital. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
vebreltinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07153770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07153770.